OBJECTIVES: Donor organ utilization and shortage remain the major limitations to the opportunity of a lung transplantation (LTx). Donation after circulatory determined death (DCD) has been adopted as a source of additional organs worldwide. However, concerns about organ quality and ischaemia-reperfusion injury have limited its application. The aim of this study was to retrospectively analyse a single-centre experience in the DCD LTx and compare early and mid-term outcomes with those from a standard donation after brain death (DBD).
INTRODUCTION
Lung transplantation (LTx) is an established therapeutic option for selected patients experiencing end-stage lung disease when all other therapeutic options have been exhausted. Donor organ shortage and high early mortality as a result of primary graft dysfunction (PGD) still remain as major limitations and challenges in this field [1] [2] [3] . As a consequence of these difficulties, a number of different strategies have been used to increase the organ availability. Among these are extended-criteria organ donors, adoption of donor management protocols, livingrelated lobar transplantation, surgical downsizing of donor lungs, ex vivo lung perfusion and donation after circulatory determined death (DCD) [4] [5] [6] [7] .
In the United States, the percentage of the DCD donors has increased by 24% from 2006 to 2008 compared with a 2% decrease in the donation after brain death (DBD) [8] . To date, in the United Kingdom, the DCD programme accounts for 14% of the overall LTxs performed, and initial data suggest an equivalent of 1-year survival compared with the DBD recipients [9] . Several groups have reported that between 10% and 25% of all LTxs performed are from the DCD donors: Van De Wauwer et al. [10] report that, in their experience, 25% of organs are obtained from the DCD donors, De Vleeschauwer et al. [11] suggested that 12% of LTxs were from the DCD donors and Levvey et al. [12] , in a 5-year experience in Australia, conclude that DCD is able to provide an 'extra' 28% of organs.
Although the current data suggest good short-term survival, there is still scant evidence about longer-term outcomes [11] [12] [13] [14] . The aim of this study is to retrospectively analyse the 6-year experience of the Royal Papworth Hospital, Cambridge, UK, in LTx from controlled Maastricht Category III donors and compare the early and mid-term outcomes with those from standard DBD donors.
MATERIALS AND METHODS
The DCD lung programme was started at the Royal Papworth Hospital in March 2009. From March 2009 to March 2015, 186 LTxs were performed: 147 bilateral lung transplantations (BLTxs) (79%) and 39 single LTxs (21%). Of these, 23 recipients received organs retrieved from the DCD donors (12.4%) [15] .
During the study period, 510 controlled Maastricht Category III DCD donors were referred to our centre: 265 donors were declined because they did not meet the standard criteria for organ donation (52%), 95 donors were declined as there were no suitable recipients (18.6%), 22 were declined due to logistical issues (4.3%), in 12 cases, consent was withdrawn by relatives after the offer (2.3%), 41 were declined on inspection (8.1%), 52 did not arrest in the mandated 120-min post-withdrawal window (10.2%) and 23 were accepted and underwent transplantation (4.5%).
A comparative analysis was performed on the control group of 163 LTxs from DBD donors in the same study period. An approval for the study was obtained from the institutional review board.
None of the lungs were reconditioned with ex vivo lung perfusion.
Donor selection criteria
The selection of donors was based on the current guidelines [14, 15] . All organ donors younger than 65 years who did not have any of the following contraindications were considered suitable for lung donation: (i) chest trauma with extensive bilateral lung contusions, (ii) convincing radiological evidence of bilateral pneumonic consolidation, (iii) pre-existing structural lung changes (e.g. emphysema or multiple large bullae), (iv) previous complex intrapleural thoracic surgery or dense adhesions prohibiting safe procurement, (v) systemic arterial PO 2 <30 kPa on 100% FiO 2 and 5 cmH 2 O PEEP, (vi) bronchoscopy showing inflammation or bleeding of the airway, and recurrent secretions in the distal airways after adequate toilet and (vii) sustained peak airway pressure >30 cmH 2 O. DCD lungs were taken into consideration if the time between withdrawal of treatment and cardiac arrest (agonal time) was less than 120 min.
All patients on the LTx waiting list were separately consented for transplantation from the DCD and the DBD donors. Postoperative management and anti-infective, antiviral and immunosuppressive strategies were identical for both modalities of donation.
Maastricht Category III DCD lung retrieval procedure
Lungs are retrieved according to the national protocol by teams allocated to the zone in which the procurement takes place. The retrieval teams (cardiothoracic and abdominal) are not involved in any way with the management of the donor prior to the retrieval.
Appropriate consent is obtained from the next of kin, and the donor is brought into the preoperating room. Life-supporting treatment, including ventilatory support, is withdrawn.
At the point of treatment withdrawal, retrieval teams are already scrubbed in the operating room. After cardiac arrest occurs, a 5-min observation is required before death can be certified by a member of the donor hospital team providing evidence that there is no subsequent restoration of cardiac circulation (the 'no touch' period). After the no touch period, the donor is transferred to the operating room for multiorgan retrieval. After rapid prepping and draping, the cardiothoracic and abdominal teams commence surgery simultaneously. Two cardiothoracic surgeons are involved in the operation in order to minimize the warm ischaemic time: while the first one performs the sternotomy, the second one carries out endotracheal reintubation and bronchoscopy. Heparin is administered directly into the pulmonary artery. Topical cooling with cold water and lung inspection for collapse, consolidation, mass lesions and pleural adhesions are performed. If the lungs are accepted, an antegrade flush of Prostaglandin (500 mg) and 4 l of Perfadex V R solution (Vitrolife, Goteborg, Sweden) are administered after cannulation of the proximal pulmonary artery. The tip of the left atrial appendage is amputated to allow free drainage of pulmonary flush solution. When the antegrade perfusion is complete, 1 l of retrograde perfusion is infused through the pulmonary veins in order to obtain clear effluent from the pulmonary arteries. The lungs are ventilated during this time to allow the proper distribution of pulmonary flush solution bilaterally and to recruit any atelectatic regions. Then, the lungs are retrieved in the standard way, stored in Perfadex V R solution, placed on ice for transport and implanted into recipients without further assessments.
Donation after brain death donor management protocol
In the case of retrieval from the DBD donors, each intensive care unit (ICU) is responsible for the donor management until the time of withdrawal. The cardiothoracic retrieval team initiates invasive haemodynamic assessment and heart and lung evaluation. This involves the insertion of lines, transoesophageal echocardiography and fibre-optic bronchoscopy.
Definitions
A Maastricht Category III DCD donor is a patient with severe, non-recoverable brain injury where his or her next of kin have requested the cessation of life-supporting treatment in the absence of the usual brain death criteria [16] .
The withdrawal time or 'agonal period' is the time from treatment withdrawal to circulatory arrest. The asystolic or acirculatory warm time is the time from circulatory arrest to the organs perfusion with cold preservation solution in situ. The cold ischaemic time is defined as the time from the start of antegrade pulmonary flush to the time of the implanted lungs reperfusion. The total ischaemic time is defined as the time between the DCD cardiac arrest, or the aortic cross-clamp in the DBD, and the reperfusion of the second implanted lung in the recipient [17] .
The definition and grade of PGD are based on the ISHLT Working Group on Primary Dysfunction Report [18] . It refers to severe hypoxaemia after surgery, lung oedema and radiographic evidence of diffuse pulmonary infiltration without other identifiable causes (i.e. rejection, infection or left atrial hypertension). PaO 2 /FiO 2 <200 mmHg is considered as PGD 3; PaO 2 /FiO 2 between 200 and 300 mmHg is considered as PGD 2 and PaO 2 / FiO 2 >300 mmHg is considered as PGD 0 or 1 based on the findings of the chest X-ray.
Bronchiolitis obliterans syndrome (BOS) refers to graft deterioration, secondary to persistent airflow obstruction. According to the ISHLT recommendations, the recipient is diagnosed with BOS in the case of a greater than 20% drop in the best forced expiratory value (FEV1) obtained post-transplantation and measured 3 weeks apart [19] .
Statistical analysis
For continuous variables, data are represented as mean and standard deviation or as median and interquartile range; for categorical variables, data are represented as frequency and percentage. In the comparison analysis for outcome, a WilcoxonMann-Whitney test was used for continuous variables, and Yates corrected v 2 test or Fisher's test was used for categorical variables.
All the statistical tests were 2-sided, and P-values of <0.05 were considered statistically significant.
The Kaplan-Meier method was used to assess patients' survival and freedom from BOS; log-rank tests were used to assess statistical significant differences between the DCD and DBD groups.
RESULTS

Donors and ischaemic times
A comparison of the overall characteristics between the DCD and DBD donors is presented in Table 1 . No differences were found in age, gender, history of smoking, cause of death and mechanical ventilation time. The total ischaemic time did not differ significantly between the 2 groups: 322 min for the DCD donors vs 323.5 min for the DBD donors. In the DCD group, the median withdrawal time was 14 min, and the median asystolic warm time was 20 min (Table 1 and Fig. 1 ).
Recipients
Characteristics of the recipients are shown in Table 2 . No differences were found with regard to gender, comorbidities, preoperative FEV 1 and forced vital capacity, waiting list days before transplant and rate of procedures on cardiopulmonary bypass. The only significant differences were that patients who received the DCD lungs were older (58.1 ± 7.4 compared with 50.4 ± 13.7 in the DBD group, P = 0.009) and a significantly higher proportion of patients who received DBD lungs had cystic fibrosis as underlying disease (19.6% compared with no patients in the DCD group, P = 0.02). The type of procedure performed showed a trend towards more BLTxs performed in the DBD group (81.6% vs 60.9% in the DCD group, P = 0.05).
Early and late outcomes are presented in Table 2 . The DCD group was comparable to the control group with regard to duration of mechanical ventilation, incidence of postoperative extracorporeal membrane oxygenation support for severe PGD, ICU stay and hospital length of stay. PGD rate and grading were not significantly different between groups at 24 and 72 h after transplant (Fig. 2) .
Airway anastomotic complications were defined as dehiscence, excessive granulation tissue formation, fistulae and significant anastomotic stenosis, which required bronchoscopic interventions such as balloon dilatation, stent positioning or debridement. This was observed in 5 patients in the DCD group (21.7%) and in 23 patients in the DBD group (14.1%), P = 0.52. No differences in incidence and grading of rejection were found between the groups.
Ninety-day mortality was comparable: 8.7% in the DCD group and 8.6% in the DBD group (P > 0.09). No differences were found in early mortality also in the comparison between single LTx and BLTx. Actuarial survival rate in the subgroup of BLTx at 1 year and 5 years was 75% and 51% for the DCD group and 82% and 61% for the DBD group, respectively (P = 0.12) (Fig. 3) . In the DBD group, 32 patients (19.6%) developed BOS after a mean of 872.2 ± 466.2 days and in the DCD group, 1 patient developed BOS after 531 days (4.3%). Actuarial freedom from BOS in the subgroup of BLTx at 1 year and 5 years was 100% and 83% for the DCD group and 100% and 42% for the DBD group, respectively (P = 0.64) (Fig. 4) .
DISCUSSION
We have retrospectively evaluated our single-centre experience in the DCD LTx. Our analyses demonstrate that early and late outcomes of Category III DCD lung recipients are comparable with those of the DBD recipients. The utilization of the DCD donor lungs has allowed us to increase LTx activity by 14% during the study period. These results confirm the findings reported by other centres that DCD is a good strategy to expand the donor pool and increase the probability of a transplant [7, [9] [10] [11] 13] .
The gap between the number of potential recipients and the number of LTx performed widens each year and, thus, there is an increasing unmet need. This is mainly related to the low utilization of donor lungs, in particular, with only 20% of the DBD multiorgan donors successfully donating lungs [1] . DCD has been proposed as a source of additional organs worldwide and comparable or even better results than DBD in kidney and liver transplants have already been reported [20, 21] . The very first human lung transplant came from a DCD donor and its feasibility is well established in an experimental animal study and in clinical practice [20] [21] [22] [23] . However, its widespread adoption remains somewhat limited, and this, in part, maybe related to legislative regulation preventing this form of organ donation. In addition, there remain some concerns over the risk of organ injury and graft dysfunction as a result of prolonged cardiopulmonary instability during the agonal period. Moreover, the DCD lungs might be susceptible to aspiration during the same period [24] . On the other hand, it does avoid significant injury from brain stem death [1] ; this event is characterized by the release of proinflammatory, endocrine and immunological mediators and of catecholamine-the 'catecholamine storm'-in the systemic circulation. The organ response can increase the susceptibility of ischaemia-reperfusion injury and lead to neurogenic pulmonary oedema [24] .
Another point of debate regarding the DCD donors is the risk of pulmonary vessel thrombosis during the asystolic warm period: for ethical reasons, in many countries, the retrieval team is not allowed to administer heparin in the donor until the declaration of death. However, experimental data suggest that intravascular administration of heparin immediately after death or fibrinolytic agents added to the antegrade/retrograde flush results in a lower formation of pulmonary microthrombi and good graft function [25] . To date, several case series of the DCD lungs have been reported. The Madrid group is the only one using lungs from Category I DCD donors: in a series of 17 recipients, the authors reported higher rates of PGD and BOS. They concluded that longer ischaemic times in the DCD lungs were directly associated with early poorer outcomes [4] . These results may be biased by the small sample size and the warm ischaemic time reported (118 min, range 44-192 min), which are longer than those reported in our experience and in other series on Category III donors.
Case series on Category III donors have shown very satisfactory outcomes. In Canada, 55 LTxs from the DCD donors were performed in 6 years with comparable 1-, 3-and 5-year survivals with the DBD group of the same study period [26] . De Vleeschauwer et al. [11] compared 21 DCD LTxs with 154 DBD LTxs: survival at 1 year and 3 years and freedom from PGD and BOS were not different between the groups. Van De Wauwer et al. [10] reported a lower incidence of BOS in 35 DCD recipients compared with 77 DBD recipients, and no differences in survival and PGD were found. From the United Kingdom, Zych et al. [27] reported their experience on 26 DCD LTxs: survival, incidence of PGD and BOS were not different from those of the DBD cohort. Mason et al. [28] reported a retrospective review of the outcomes in 36 LTxs from DCD donors and suggested that the 2-year survival rate was equivalent to that after DBD. Levvey et al. [12] reported the 5-year Australian multicentre experience on 72 DCD lungs with excellent results compared with the DBD donors (1-and 5-year actuarial survival was 97% and 90% vs 90% and 61%, respectively). Ruttens et al. [29] reported their long-term experience on DCD lung with the results comparable to the DBD control group in terms of chronic lung allograft dysfunction and overall 5-year survival. Finally, a recent systematic review and meta-analysis by Krutsinger et al. [30] concluded that survival, PGD, acute rejection and airway complications after LTx from DCD are comparable to those after LTx from DBD.
Our results are in line with the reports of the Category III donors in the literature: early survival, acute rejection and airway complications requiring endoscopic treatment are comparable in the DBD control group. Also, the incidence of severe PGD in the DCD donor group was not higher than that in the DBD group (26.1% and 17.4% at 24 h and 72 h vs 20.8% and 12.3% at 24 h and 72 h, respectively, P = NS). None of the patients who received DCD lungs required postoperative extracorporeal membrane oxygenation for graft dysfunction.
Further, by analysing the subgroups of BLTxs with a follow-up time of up to 5 years, this report shows good and equivalent outcomes in 1-and 5-year survival (75% and 51% for the DCD group and 82% and 61% for the DBD group, respectively, P = NS) and lung allograft function (100% and 83% for the DCD group and 100% and 42% for the DBD group, respectively, P = NS).
The number of DCD lungs accepted and transplanted versus the overall DCD lungs offered during the study period was lower than that reported by other centres (4.5% vs 33.6% in an Australian experience and 17.5% in an American experience) [12, 13] . However, it has to be underlined that, in our cohort of donors, more than 50% of DCD lungs were declined because they did not meet the standard guidelines criteria for organ donation.
Limitations
The retrospective and single-centre design and the relatively small sample size are the main limitations of the study. Moreover, the baseline recipient analysis showed significant differences in terms of age and underlying disease. The reason was probably the lack of confidence in the new DCD programme at the beginning of the study period; therefore, younger patients were preferably addressed in the DBD programme.
CONCLUSION
In conclusion, the results of this study show that DCD LTx is a clinical option with comparable short-and medium-term outcomes with the DBD LTx. DCD donors can, therefore, be used as tool to expand the lung donor pool.
